Brian P. Sko

Sarepta Therapeutics Inc (NASDAQ: SRPT) gained more than 60 percent Wednesday on news that it expects to complete an approval application for its lead drug candidate by mid-2015. The company's shares closed at $26.44, up $10.06. Sarepta is likely to go "significantly higher over...